Decrease in penbutolol central response as a cause of changes in its serum protein binding.

Article Details

Citation

Copy to clipboard

Martinez Jorda R, Aguirre C, Calvo R, Rodriguez-Sasiain JM, Erill S

Decrease in penbutolol central response as a cause of changes in its serum protein binding.

J Pharm Pharmacol. 1990 Mar;42(3):164-6.

PubMed ID

1974610 [ View in PubMed

]

Abstract

Penbutolol is a beta-adrenoceptor antagonist that is extensively bound to alpha 1-acid glycoprotein (alpha 1-AGP), a protein that increases in inflammatory diseases thereby binding more drug in such conditions. Changes in serum binding can lead to modifications in the pharmacokinetics and pharmacodynamics of a drug, therefore, the central effect (as the anticonvulsant response) and brain uptake of penbutolol given intravenously to mice with experimental inflammation have been measured. A significant decrease of the central effect of penbutolol and its brain uptake was seen in diseased when compared with control animals (P less than 0.01). A parallel decrease in free fraction of penbutolol in diseased vs normal animals was detected. These results suggest that there is an increase in serum binding of basic drugs related to increments in alpha 1-AGP concentration, which reduces their central pharmacological effect.

DrugBank Data that Cites this Article

Drugs

Penbutolol

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Penbutolol	Alpha-1-acid glycoprotein 1	Protein	Humans	Unknown	Other/unknown	Details